A new report published on Tuesday 25 February, produced by R-Health Consult and commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA), analyses the economic and health benefits of investing in five noncommunicable diseases in the EU.
The report focuses on stroke, ischaemic heart disease, type 2 diabetes, chronic obstructive pulmonary disease (COPD) and breast cancer in the 27 EU Member States, and makes recommendations on how to reduce mortality,...